Decheng Capital LLC Has $3.21 Million Stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Decheng Capital LLC cut its position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 13.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,019,762 shares of the company's stock after selling 318,333 shares during the quarter. Zentalis Pharmaceuticals accounts for about 0.9% of Decheng Capital LLC's holdings, making the stock its 18th biggest holding. Decheng Capital LLC owned about 2.81% of Zentalis Pharmaceuticals worth $3,211,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Corton Capital Inc. bought a new position in shares of Zentalis Pharmaceuticals during the 4th quarter valued at about $32,000. Captrust Financial Advisors bought a new stake in shares of Zentalis Pharmaceuticals in the 4th quarter worth $33,000. Cerity Partners LLC grew its holdings in shares of Zentalis Pharmaceuticals by 58.7% in the first quarter. Cerity Partners LLC now owns 20,501 shares of the company's stock worth $33,000 after acquiring an additional 7,579 shares during the period. Prudential Financial Inc. bought a new stake in shares of Zentalis Pharmaceuticals in the fourth quarter worth $39,000. Finally, Vident Advisory LLC purchased a new position in Zentalis Pharmaceuticals during the fourth quarter valued at $45,000.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on ZNTL. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 target price on shares of Zentalis Pharmaceuticals in a report on Thursday, May 15th. Wedbush restated a "neutral" rating and issued a $4.00 target price on shares of Zentalis Pharmaceuticals in a research note on Thursday, May 15th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, Zentalis Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $8.37.

Zentalis Pharmaceuticals Trading Down 2.9%

ZNTL traded down $0.04 on Friday, hitting $1.34. 416,410 shares of the company's stock were exchanged, compared to its average volume of 751,526. The firm has a market cap of $96.41 million, a PE ratio of -0.43 and a beta of 1.71. Zentalis Pharmaceuticals, Inc. has a twelve month low of $1.01 and a twelve month high of $5.44. The stock has a fifty day moving average of $1.36 and a two-hundred day moving average of $1.60.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.67) EPS for the quarter, meeting analysts' consensus estimates of ($0.67). On average, analysts predict that Zentalis Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.